Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …

Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of
cells commonly termed “cancer stem cells” that has been proposed to be a strong driving …

Development of biosensing platforms plays a key role in research settings for identification
of biomarkers and in clinical applications for diagnostics. Biosensors based on nucleic acids …

DNA methylation, an epigenetic modification, regulates gene transcription and maintains
genome stability. DNA methyltransferase (DNMT) inhibitors can activate silenced genes at …

The DNA methyltransferase (DNMT) inhibitors azacytidine and decitabine are the most
successful epigenetic drugs to date and are still the most widely used as epigenetic …

Epigenetic events, which are somatically inherited through cell division, are potential drivers
of acquired drug resistance in cancer. The high rate of epigenetic change in tumours …

Preclinical studies have shown that hypomethylating agents reverse platinum resistance in
ovarian cancer. In this phase II clinical trial, based upon the results of our phase I dose …

Cisplatin is used for the treatment of many types of solid cancers. While testicular cancers
respond remarkably well to cisplatin, the therapeutic efficacy of cisplatin for other solid …

Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …